TCT-532 Implantation Of Bioresorbable Vascular Scaffolds After Acute Coronary Syndrome Is Associated With Reduced Early Neointimal Growth And Strut Coverage  by Giblett, Joel P. et al.
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5 B217Medical, Mountain View, CA) with thinner strut thickness (120
micron) in a porcine coronary artery model.
METHODS Fifty-four coronary arteries of 18 Yucatan mini-swine
received either sirolimus-eluting BRS with regular strut thickness (150
mm, n¼16), lower strut thickness (120 mm, n¼16) or BVS (Absorb, n¼16)
were harvested for histopathology following imaging with angiog-
raphy and optical coherence tomography (OCT) at 28 (n¼8 for each
group) and 90 days (n¼8 for each group).
RESULTS At 28 days, 120mm-BRS showed less % diameter stenosis
(128%) by angiography compared to 150mm-BRS (1913%) and BVS
(2712%, p<0.05). Histopathology revealed smaller neointimal area
(1.680.30 mm2 vs. 150mm-BRS 2.080.50 mm2, and BVS
2.570.66mm2, p¼0.007) and % Area Stenosis (AS) in 120mm-BRS
group as well; both BRS groups had lower peri-strut inﬂammation
score compared to the BVS group (150mm-BRS: 00, 120mm-BRS:
0.170.36 vs. BVS: 0.420.39, p¼0.04). At 90 days, OCT and histo-
logical evaluation showed comparable neointimal formation (%AS:
150mm-BRS: 366%, 120mm-BRS: 3110% vs. BVS: 3814%, p¼0.40)
and comparable qualitative features of arterial healing between both
BRS groups and BVS.
CONCLUSIONS The novel sirolimus-eluting BRS with thinner (120
mm) struts showed adequate acute and chronic biomechanical
behavior and durability when compared to regular strut BRS and BVS,
and a favorable effect on neointimal inhibition and healing response
up to 90 days after implantation.
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BACKGROUND Due to the inherent limitations of bioabsorbable
polymeric materials, overexpansion may be very limited for some
bioresorbable scaffolds (BRS) such as the benchmark Absorb BVS. The
unique biomechanical properties of the novel sirolimus eluting BRS
(Amaranth Medical, Mountain View, CA) may allow it to be safely
upsized. The aim of the study was to evaluate the biomechanical
properties and healing of the sirolimus eluting BRS that have been
postdilated by 0.55 and 0.8mm beyond the nominal diameters within
the pressure-diameter compliance chart range.
METHODS Twenty eight coronary arteries of 8 healthy Yucatan min-
iswine underwent implantation of novel sirolimus eluting BRS.
Upsizing by postdilation was performed up to 0.55 mm (PLUS 0.55,
n¼6) or up to 0.8 mm (PLUS 0.8 n¼6) in a manner maintaining
consistent stent-to-artery ratio of average 110%, thus ensuring only
overexpansion of the scaffold but consistent level of arterial injury.
Non postdilated segments served as control (Control, n¼ 16). OCT and
angiographic follow up were performed at 28 and 90 days follow up.
RESULTS There was no statistical difference between tested groups in
terms of acute recoil (PLUS 0.55: 9.55.5%, PLUS 0.8: 9.77.6%,
Control 59.5%, p¼0.45). QCA analysis after 28 days showed similar
late lumen loss (PLUS 0.55: 0.480.17, PLUS 0.8: 0.290.29, Control:
0.650.50 mm, p¼0.22), % diameter stenosis was smaller in PLUS 0.8
compared to Control group (PLUS 0.55: 18.69.15%, PLUS 0.8:
102.02%, Control: 24.65.69, p<0.01). 90-day angiographic out-
comes were comparable in terms of late lumen loss (PLUS 0.55:
0.580.29, PLUS 0.8: 0.380.2, Control: 0.430.43 mm, p¼0.42) and
% diameter stenosis (PLUS 0.55: 179.3%, PLUS 0.8: 17.17.1%, Con-
trol: 18.212.5, p¼0.97). OCT analysis showed comparable neoinitmal
area (PLUS 0.55: 2.20.89, PLUS 0.8: 1.320.57, Control:
2.110.87 mm2, p¼0.13) and neointimal thickness (PLUS 0.55:
0.250.1, PLUS 0.8: 0.140.06, Control: 0.250.1 mm, p¼0.06) at 90
days follow up. No scaffold fractures were observed in any of the
studied groups.
CONCLUSIONS Overexpansion up to 0.8mm of novel, high strength
sirolimus eluting BRS is not associated with worse angiographic out-
comes, neointimal formation or biomechanical issues such as stent
deformation or fracture, neither acutely nor chronically.
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BACKGROUND Previous studies have suggested that neointimal
growth and strut coverage is reduced in patients with acute coronary
syndrome (ACS) that receive metallic stents. The BVS is a novel
technology and use of more biocompatible devices may facilitate early
neointimal growth and subsequent earlier strut coverage. We aimed to
assess whether neointimal growth is affected by clinical presentation,
in a population of patients undergoing bioresorbable vascular scaffold
(BVS) implantation.
METHODS BVS were implanted in patients either for stable angina
(SA) or ACS using optical coherence tomography (OCT) guidance.
Repeat OCT was performed at follow-up (median 74 days), and BVS
analyzed at 1mm longitudinal intervals. OCT analysis (Figure)
included measures of scaffold, luminal and ﬂow area, as well as
assessment of strut apposition, coverage and neointimal growth.
RESULTS In total, 29 BVS were included in the analysis (62%
following ACS). There were no differences between procedural or
lesion characteristics between groups. Post-deployment, all BVS
achieved >90% predicted scaffold area with only 1.64% struts classi-
ﬁed as incompletely apposed at baseline, compared with 0.47% at
follow-up (p¼0.006). Reductions in mean scaffold (-4.0%, p¼0.01)
and ﬂow (-8.4%, p<0.001) areas were observed at follow-up, with
larger reductions in mean ﬂow area for stable patients (SA -14.514.2
vs. ACS -4.97.9%, p¼0.03). ACS patients had reduced neointimal
growth (0.510.18 vs. 0.870.37mm2, p¼0.002), and increased per-
centage of uncovered struts (2.681.67% vs. 1.430.87%, p¼0.015).
CONCLUSIONS Neointimal growth and strut coverage is reduced
following ACS in patients receiving BVS at an earlier timepoint than
previously studied. This is consistent with studies in metallic stents
and suggest use of more biocompatible devices may not necessarily
improve early strut coverage.
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